Iranian Court Demands $12.6 Billion Compensation from US for Thalassemia Patients

In a significant legal development, the 55th branch of the court addressing international affairs within Tehran’s Imam Khomeini Judicial Complex has ruled in favor of thalassemia patients who have been adversely affected by US-imposed sanctions. This ruling comes after 438 plaintiffs filed a lawsuit against 17 natural and legal persons affiliated with the US administration, claiming that these sanctions severely impacted their access to essential medications.

The court’s decision, announced on Wednesday, imposes substantial financial responsibilities on the US government and its officials. The total damages awarded amount to an eye-popping $12.615 billion, intended to cover material, moral, and punitive damages suffered by the plaintiffs.

Key highlights from the court’s ruling include:

• Impact of Sanctions: The court noted that the imposition of secondary and pharmaceutical sanctions led to a critical shortage of original and high-quality medications for thalassemia patients.
• Use of Low-Quality Medicines: Due to the sanctions, patients were forced to rely on low-quality drugs, resulting in severe health complications and increased treatment costs.
• Health Consequences: The lack of adequate medicines heightened drug allergies and worsened the pain and suffering experienced by patients.
• Psychological and Social Effects: The court emphasized that the adverse effects of inadequate treatment not only caused psychological suffering but also limited patients’ social interactions, such as attending school and job opportunities.

The ruling elaborated on the extensive damages inflicted on these patients, highlighting that the sanctions have not only jeopardized their physical health but also imposed significant psychological burdens. The court stated, “In fact, the lack of the required medicines for thalassemia patients led to an increase in these patients’ drug allergy and exacerbation of pain and suffering caused by the use of other drugs.”

Furthermore, the court pointed out that the US government’s unilateral sanctions constitute a blatant violation of human rights, labeling them as “criminal acts against the civilian population.” This assertion underlines the serious implications of such sanctions, which have indiscriminately affected individuals in need of medical protection.

The court’s ruling is a pivotal moment for thalassemia patients and their families, as it not only acknowledges the suffering endured due to inadequate access to medication but also sets a precedent for holding nations accountable for the consequences of their sanctions.

In conclusion, this landmark ruling serves as a powerful statement against the detrimental effects of sanctions on vulnerable populations. It underscores the urgent need for international dialogue and cooperation to ensure that humanitarian considerations are prioritized over political agendas. The verdict not only seeks to compensate the patients but also aims to restore their dignity and access to essential healthcare services.

As the situation unfolds, it will be crucial to monitor the response from the US government and the broader implications of this ruling for international relations and humanitarian law.